1. Home
  2. CHCO vs LQDA Comparison

CHCO vs LQDA Comparison

Compare CHCO & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CHCO
  • LQDA
  • Stock Information
  • Founded
  • CHCO 1957
  • LQDA 2004
  • Country
  • CHCO United States
  • LQDA United States
  • Employees
  • CHCO N/A
  • LQDA N/A
  • Industry
  • CHCO Major Banks
  • LQDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • CHCO Finance
  • LQDA Health Care
  • Exchange
  • CHCO Nasdaq
  • LQDA Nasdaq
  • Market Cap
  • CHCO 1.8B
  • LQDA 1.7B
  • IPO Year
  • CHCO N/A
  • LQDA 2018
  • Fundamental
  • Price
  • CHCO $128.94
  • LQDA $27.28
  • Analyst Decision
  • CHCO Hold
  • LQDA Strong Buy
  • Analyst Count
  • CHCO 3
  • LQDA 10
  • Target Price
  • CHCO $132.33
  • LQDA $31.40
  • AVG Volume (30 Days)
  • CHCO 84.0K
  • LQDA 3.1M
  • Earning Date
  • CHCO 10-23-2025
  • LQDA 08-12-2025
  • Dividend Yield
  • CHCO 2.46%
  • LQDA N/A
  • EPS Growth
  • CHCO 6.95
  • LQDA N/A
  • EPS
  • CHCO 8.30
  • LQDA N/A
  • Revenue
  • CHCO $300,872,000.00
  • LQDA $19,322,000.00
  • Revenue This Year
  • CHCO $9.69
  • LQDA $362.31
  • Revenue Next Year
  • CHCO $1.71
  • LQDA $418.29
  • P/E Ratio
  • CHCO $15.48
  • LQDA N/A
  • Revenue Growth
  • CHCO 4.61
  • LQDA 30.20
  • 52 Week Low
  • CHCO $102.22
  • LQDA $8.75
  • 52 Week High
  • CHCO $137.28
  • LQDA $28.82
  • Technical
  • Relative Strength Index (RSI)
  • CHCO 61.72
  • LQDA 70.92
  • Support Level
  • CHCO $127.23
  • LQDA $27.23
  • Resistance Level
  • CHCO $131.07
  • LQDA $28.82
  • Average True Range (ATR)
  • CHCO 2.57
  • LQDA 1.42
  • MACD
  • CHCO 0.77
  • LQDA -0.08
  • Stochastic Oscillator
  • CHCO 85.53
  • LQDA 80.44

About CHCO City Holding Company

City Holding Co is a financial holding company. The company conducts its principal activities through its wholly-owned subsidiary, City National Bank of West Virginia (City National). Through the bank, it provides banking, trust and investment management, and other financial solutions through its network of banking offices located in the states of West Virginia, Virginia, southeastern Ohio, and Kentucky. It offers various products and services such as overdraft facilities, savings accounts, credit cards and debit cards, loans for various purposes, investment advisory, securities brokerage, insurance products, and others. The company's business activities are currently limited to one reportable business segment, which is community banking.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Share on Social Networks: